Call +1 (833) 552-7181 or Contact us Earn $25 in coupons on your first order with Aladdin!
Toggle Nav
My Cart
Search
Advanced Search
Menu
Sign In
྾
main product photo

Ziltivekimab (anti-IL-6) - Primary antibody, specific to IL6, >95%, high purity, Human IgG1, Antibody of Fc fragment of IgG receptor and transporter

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
Features and benefits
  • Host species: Human
  • Species reactivity(Reacts with): Human
  • Isotype: Human IgG1
  • Conjugation: Unconjugated
Item Number
Ab175709
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab175709-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$59.90
Ab175709-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$279.90
Ab175709-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$739.90
Ab175709-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,189.90
Add to Wish List Compare
Bulk Order  DATASHEET

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

View related series
Click to view target information: FCGRT Click to view target information: IL6
Accession#:P05231 Antibody Fc fragment of IgG receptor and transporter Antibody Gene ID:3569 IL6

Basic Description

Product NameZiltivekimab (anti-IL-6) - Primary antibody, specific to IL6, >95%, high purity, Human IgG1
SynonymsInterleukin BSF 2 antibody | B cell differentiation factor antibody | B cell stimulatory factor 2 antibody | B-cell stimulatory factor 2 antibody | BSF 2 antibody | BSF-2 antibody | BSF2 antibody | CDF antibody | CTL differentiation factor antibody | Cyto
Specifications & PurityExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
Host speciesHuman
SpecificityIL6
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action TypeBINDING AGENT
Mechanism of actionAntibody of Fc fragment of IgG receptor and transporter
Product Description

Ziltivekimab (anti-IL-6) is a human anti-IL-6 monoclonal antibody that is effective in reducing serum CRP. Ziltivekimab (anti-IL-6) has anti-inflammatory activity and may be used in studies of chronic systemic inflammation and cardiovascular disease associated with CKD[1].

Product Properties

IsotypeHuman IgG1
Light Chain Typekappa
SDS-PAGE26.4 kDa (Light Chain) & 49.7 kDa (Heavy Chain), under reducing conditions; 175.3 kDa, under non-reducing conditions.
Purification MethodProtein A purified
Purity>95%
FormLiquid
ConcentrationLot by Lot
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS2226654-05-1

Images

Ziltivekimab (anti-IL-6) (Ab175709) - ELISA
Immobilized hu-IL-6 at 2 μg/mL can bind Ziltivekimab (anti-IL-6) (Ab175709) with the EC₅₀ of 103.3 ng/mL.

Ziltivekimab (anti-IL-6) (Ab175709) - SEC
The purity of Ziltivekimab (anti-IL-6) (Ab175709) is more than 95% verified by HPLC.

Associated Targets(Human)

FCGRT Tclin IgG receptor FcRn large subunit p51 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
IL6 Tclin Interleukin-6 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
FCGRT Tclin IgG receptor FcRn large subunit p51 (445 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot NumberCertificate TypeDateItem
ZJ24F0404190Certificate of AnalysisApr 07, 2024 Ab175709
ZJ24F0404189Certificate of AnalysisApr 07, 2024 Ab175709
ZJ24F0404188Certificate of AnalysisApr 07, 2024 Ab175709

Related Documents

 SDS

 Specification Sheet

References

1. Finch DK, Sleeman MA, Moisan J, Ferraro F, Botterell S, Campbell J, Cochrane D, Cruwys S, England E, Lane S et al..  (2011)  Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics..  J Mol Biol,  411  (4): (791-807).  [PMID:21723291] [10.1021/op500134e]
2. Zhong H, Davis A, Ouzounova M, Carrasco RA, Chen C, Breen S, Chang YS, Huang J, Liu Z, Yao Y et al..  (2016)  A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors..  Cancer Res,  76  (2): (480-90).  [PMID:26744529] [10.1021/op500134e]
3. Kim GW, Lee NR, Pi RH, Lim YS, Lee YM, Lee JM, Jeong HS, Chung SH.  (2015)  IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future..  Arch Pharm Res,  38  (5): (575-84).  [PMID:25648633] [10.1021/op500134e]
4. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC.  (2003)  Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex..  Science,  300  (5628): (2101-4).  [PMID:12829785] [10.1021/op500134e]
5. Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S et al..  (2014)  Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling..  MAbs,  6  (3): (774-82).  [PMID:24670876] [10.1021/op500134e]
6. Kang S, Tanaka T, Narazaki M, Kishimoto T.  (2019)  Targeting Interleukin-6 Signaling in Clinic..  Immunity,  50  (4): (1007-1023).  [PMID:30995492] [10.1016/j.immuni.2019.03.026]
7. Q Y Chen.  (1992-09-01)  [Stable and efficient expression of human interleukin-6 cDNA in mammalian cells after gene transfer]..  Zhonghua zhong liu za zhi [Chinese journal of oncology],  14  ((5)): (340-344).  [PMID:1291290]
8. H C van Zaanen,R P Koopmans,L A Aarden,H J Rensink,J M Stouthard,S O Warnaar,H M Lokhorst,M H van Oers.  (1996-09-15)  Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop..  The Journal of clinical investigation,  98  ((6)): (1441-1448).  [PMID:8823310]
9. Kim D, Won HY, Hwang ES, Kim YK, Choo HP..  (2017)  Synthesis of benzoxazole derivatives as interleukin-6 antagonists..  Bioorg Med Chem,  25  (12): (3127-3134).  [PMID:28442260] [10.1016/j.bmc.2017.03.072]
10. May, L T LT, Shaw, J E JE, Khanna, A K AK, Zabriskie, J B JB and Sehgal, P B PB..  (1991)  Marked cell-type-specific differences in glycosylation of human interleukin-6..  Cytokine,      [PMID:1883960]
11. Lütticken, C C, Krüttgen, A A, Möller, C C, Heinrich, P C PC and Rose-John, S S..  (1991)  Evidence for the importance of a positive charge and an alpha-helical structure of the C-terminus for biological activity of human IL-6..  FEBS letters,    (6):   [PMID:2037043]
12. Clogston, C L CL, Boone, T C TC, Crandall, B C BC, Mendiaz, E A EA and Lu, H S HS..  (1989)  Disulfide structures of human interleukin-6 are similar to those of human granulocyte colony stimulating factor..  Archives of biochemistry and biophysics,      [PMID:2472117]
13. Ming, J E JE, Cernetti, C C, Steinman, R M RM and Granelli-Piperno, A A..  (1989)  Interleukin 6 is the principal cytolytic T lymphocyte differentiation factor for thymocytes in human leukocyte conditioned medium..  The Journal of molecular and cellular immunology : JMCI,      [PMID:2610854]
14. Tonouchi, N N, Miwa, K K, Karasuyama, H H and Matsui, H H..  (1989)  Deletion of 3' untranslated region of human BSF-2 mRNA causes stabilization of the mRNA and high-level expression in mouse NIH3T3 cells..  Biochemical and biophysical research communications,    (15):   [PMID:2789513]
15. Zilberstein, A A, Ruggieri, R R, Korn, J H JH and Revel, M M..  (1986)  Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines..  The EMBO journal,      [PMID:3023045]
16. Wong, G G GG, Witek-Giannotti, J J, Hewick, R M RM, Clark, S C SC and Ogawa, M M..  (1988)  Interleukin 6: identification as a hematopoietic colony-stimulating factor..  Behring Institute Mitteilungen,      [PMID:3266463]
17. Van Damme, J J and 5 more authors..  (1988)  Separation and comparison of two monokines with lymphocyte-activating factor activity: IL-1 beta and hybridoma growth factor (HGF). Identification of leukocyte-derived HGF as IL-6..  Journal of immunology (Baltimore, Md. : 1950),    (1):   [PMID:3279116]
18. Brakenhoff, J P JP, de Groot, E R ER, Evers, R F RF, Pannekoek, H H and Aarden, L A LA..  (1987)  Molecular cloning and expression of hybridoma growth factor in Escherichia coli..  Journal of immunology (Baltimore, Md. : 1950),    (15):   [PMID:3320204]
19. Yasukawa, K K and 6 more authors..  (1987)  Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene..  The EMBO journal,      [PMID:3500852]
20. May, L T LT, Helfgott, D C DC and Sehgal, P B PB..  (1986)  Anti-beta-interferon antibodies inhibit the increased expression of HLA-B7 mRNA in tumor necrosis factor-treated human fibroblasts: structural studies of the beta 2 interferon involved..  Proceedings of the National Academy of Sciences of the United States of America,      [PMID:3538015]
21. Haegeman, G G and 5 more authors..  (1986)  Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts..  European journal of biochemistry,    (15):   [PMID:3758081]
22. Breton, J J and 8 more authors..  (1995)  Structure, stability and biological properties of a N-terminally truncated form of recombinant human interleukin-6 containing a single disulfide bond..  European journal of biochemistry,    (15):   [PMID:7851440]
23. Nishimura, C C, Watanabe, A A, Gouda, H H, Shimada, I I and Arata, Y Y..  (1996)  Folding topologies of human interleukin-6 and its mutants as studied by NMR spectroscopy..  Biochemistry,    (9):   [PMID:8555185]
24. Somers, W W, Stahl, M M and Seehra, J S JS..  (1997)  1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling..  The EMBO journal,    (3):   [PMID:9118960]
25. Xu, G Y GY and 6 more authors..  (1997)  Solution structure of recombinant human interleukin-6..  Journal of molecular biology,    (2):   [PMID:9159484]
26. Fishman, D D and 6 more authors..  (1998)  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis..  The Journal of clinical investigation,    (1):   [PMID:9769329]
27. Foster, C B CB and 11 more authors..  (2000)  An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus..  Blood,    (1):   [PMID:11001912]
28. Ota, N N and 8 more authors..  (2001)  A nucleotide variant in the promoter region of the interleukin-6 gene associated with decreased bone mineral density..  Journal of human genetics,      [PMID:11355017]
29. Chung, Hye Won HW and 8 more authors..  (2003)  Association of interleukin-6 promoter variant with bone mineral density in pre-menopausal women..  Journal of human genetics,      [PMID:12768442]
30. Nemeth, Elizabeta E and 6 more authors..  (2004)  IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin..  The Journal of clinical investigation,      [PMID:15124018]
31. Wolsk, Emil E, Mygind, Helene H, Grøndahl, Thomas S TS, Pedersen, Bente K BK and van Hall, Gerrit G..  (2010)  IL-6 selectively stimulates fat metabolism in human skeletal muscle..  American journal of physiology. Endocrinology and metabolism,      [PMID:20823453]
32. Ellingsgaard, Helga H and 20 more authors..  (2011)  Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells..  Nature medicine,    (30):   [PMID:22037645]
33. Taniguchi, Koji K and 17 more authors..  (2015)  A gp130-Src-YAP module links inflammation to epithelial regeneration..  Nature,    (5):   [PMID:25731159]
34. Tagliabracci, Vincent S VS and 14 more authors..  (2015)  A Single Kinase Generates the Majority of the Secreted Phosphoproteome..  Cell,    (18):   [PMID:26091039]
35. Larsen, Jakob Vejby JV and Petersen, Claus Munck CM..  (2017)  SorLA in Interleukin-6 Signaling and Turnover..  Molecular and cellular biology,    (1):   [PMID:28265003]
36. Hirano, T T and 9 more authors..  (1986)  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin..  Nature,      [PMID:3491322]

Solution Calculators

Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy Sales Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.